MCID: CND002
MIFTS: 53

Conduct Disorder

Categories: Mental diseases

Aliases & Classifications for Conduct Disorder

MalaCards integrated aliases for Conduct Disorder:

Name: Conduct Disorder 12 77 56 45 15 17 74

Classifications:



External Ids:

Disease Ontology 12 DOID:12995
ICD9CM 36 312.9
MeSH 45 D019955
NCIt 51 C89329
ICD10 34 F91 F91.9
UMLS 74 C0149654

Summaries for Conduct Disorder

Disease Ontology : 12 A specific developmental disorder marked by a pattern of repetitive behavior wherein the rights of others or social norms are violated.

MalaCards based summary : Conduct Disorder is related to impulse control disorder and oppositional defiant disorder. An important gene associated with Conduct Disorder is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Transmission across Chemical Synapses and Circadian entrainment. The drugs Dopamine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and skin, and related phenotypes are Decreased viability in esophageal squamous lineage and behavior/neurological

Wikipedia : 77 Conduct disorder (CD) is a mental disorder diagnosed in childhood or adolescence that presents itself... more...

Related Diseases for Conduct Disorder

Diseases related to Conduct Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 137)
# Related Disease Score Top Affiliating Genes
1 impulse control disorder 32.9 DRD2 DRD4
2 oppositional defiant disorder 31.8 COMT DBH DRD2 DRD4 MAOA SLC6A3
3 depression 30.9 MAOA SLC6A4 TPH1
4 anxiety 30.4 COMT MAOA SLC6A4 TPH1
5 bipolar disorder 30.0 COMT DRD2 SLC6A3 SLC6A4 TPH1
6 borderline personality disorder 29.9 COMT MAOA SLC6A4 TPH1
7 antisocial personality disorder 29.8 ALDH2 COMT DRD2 MAOA SLC6A3 SLC6A4
8 alcohol abuse 29.8 ALDH2 DRD2 DRD4 SLC6A4
9 drug dependence 29.7 DRD2 POMC SLC6A4
10 autism spectrum disorder 29.5 OXTR RBFOX1 SLC6A4
11 personality disorder 29.5 ALDH2 COMT DRD2 DRD4 MAOA SLC6A3
12 tic disorder 29.4 DRD2 DRD4 DRD5 SLC6A3
13 opiate dependence 29.3 DRD2 POMC SLC6A4 TPH1
14 substance abuse 29.2 COMT DBH DRD2 DRD4 DRD5 MAOA
15 attention deficit-hyperactivity disorder 29.1 COMT DBH DRD2 DRD4 DRD5 MAOA
16 panic disorder 29.0 COMT MAOA POMC SLC6A4
17 gilles de la tourette syndrome 28.9 COMT DBH DRD2 DRD4 DRD5 SLC6A3
18 substance dependence 28.8 DRD2 DRD4 DRD5 MAOA POMC SLC6A3
19 tobacco addiction 28.5 ALDH2 COMT DRD2 MAOA SLC6A3 SLC6A4
20 disease of mental health 28.4 COMT DRD2 DRD4 MAOA OXTR POMC
21 schizophrenia 28.2 COMT DBH DRD2 DRD4 DRD5 GRIN1
22 alcohol dependence 28.1 ALDH2 COMT DBH DRD2 DRD4 MAOA
23 major depressive disorder 28.0 COMT DRD2 DRD4 MAOA OXTR POMC
24 progressive familial heart block, type ia 11.4
25 cardiomyopathy, dilated, 1e 11.3
26 heart conduction disease 11.3
27 familial progressive cardiac conduction defect 11.1
28 wolff-parkinson-white syndrome 11.1
29 cardiac conduction defect 11.1
30 pol iii-related leukodystrophies 10.6
31 atrial standstill 1 10.3
32 atypical depressive disorder 10.3 MAOA SLC6A4
33 phobia, specific 10.3 COMT MAOA
34 delusional disorder 10.3 DRD2 DRD4
35 schizophreniform disorder 10.3 COMT DRD2
36 polysubstance abuse 10.3 COMT DRD2
37 dependent personality disorder 10.3 DRD4 MAOA
38 tardive dyskinesia 10.3 COMT DRD2
39 dysthymic disorder 10.3 MAOA SLC6A4
40 kleptomania 10.2 MAOA SLC6A4
41 periodic limb movement disorder 10.2 DRD2 SLC6A4
42 alcohol-induced mental disorder 10.2 DRD2 SLC6A3 SLC6A4
43 premature ejaculation 10.2 SLC6A3 SLC6A4
44 alcoholic psychosis 10.2 DRD2 SLC6A3 SLC6A4
45 migraine without aura 10.2 DRD2 DRD4 SLC6A4
46 phobic disorder 10.2 COMT MAOA SLC6A4
47 paranoid schizophrenia 10.2 COMT MAOA SLC6A4
48 social phobia 10.2 DRD2 MAOA SLC6A4
49 separation anxiety disorder 10.2 DRD4 OXTR SLC6A3
50 schizoaffective disorder 10.2 COMT DRD2 SLC6A4

Comorbidity relations with Conduct Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Alzheimer Disease
Deficiency Anemia Schizophreniform Disorder

Graphical network of the top 20 diseases related to Conduct Disorder:



Diseases related to Conduct Disorder

Symptoms & Phenotypes for Conduct Disorder

GenomeRNAi Phenotypes related to Conduct Disorder according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.28 ALDH2 COMT DBH DRD4 DRD5 GRIN1

MGI Mouse Phenotypes related to Conduct Disorder:

47 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 ALDH2 CAMK2A COMT DBH DRD2 DRD4
2 homeostasis/metabolism MP:0005376 10.25 ALDH2 CAMK2A COMT DBH DRD2 DRD4
3 growth/size/body region MP:0005378 10.2 ALDH2 CAMK2A DBH DRD2 GRIN1 OXTR
4 cardiovascular system MP:0005385 10.19 ALDH2 COMT DBH DRD2 DRD5 GRIN1
5 endocrine/exocrine gland MP:0005379 10.13 ALDH2 COMT DBH DRD2 DRD5 OXTR
6 nervous system MP:0003631 10.1 ALDH2 CAMK2A COMT DBH DRD2 DRD4
7 mortality/aging MP:0010768 10.07 ALDH2 CAMK2A DBH DRD2 DRD5 GRIN1
8 integument MP:0010771 10.06 ALDH2 CAMK2A DBH DRD2 OXTR POMC
9 muscle MP:0005369 9.8 ALDH2 DRD2 OXTR SLC6A3 SLC6A4 TPH1
10 normal MP:0002873 9.7 DBH DRD2 DRD5 GRIN1 OXTR SLC6A3
11 reproductive system MP:0005389 9.5 ALDH2 COMT DRD2 GRIN1 OXTR RBFOX1
12 taste/olfaction MP:0005394 8.8 DRD2 GRIN1 SLC6A3

Drugs & Therapeutics for Conduct Disorder

Drugs for Conduct Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 62-31-7, 51-61-6 681
2
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 113-45-1 4158
3
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
4
Dextroamphetamine Approved, Illicit Phase 4,Phase 2 51-64-9 5826
5
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
6
Topiramate Approved Phase 4,Phase 2 97240-79-4 5284627
7
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 16590-41-3 5360515
8
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
9
Oxcarbazepine Approved Phase 4 28721-07-5 34312
10
Aripiprazole Approved, Investigational Phase 4,Not Applicable 129722-12-9 60795
11
Amphetamine Approved, Illicit, Investigational Phase 4,Phase 2 300-62-9 3007 5826
12
Carbidopa Approved Phase 4 28860-95-9 34359
13
Levodopa Approved Phase 4 59-92-7 6047
14
Citalopram Approved Phase 4 59729-33-8 2771
15
Sertraline Approved Phase 4,Phase 2 79617-96-2 68617
16
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
17
Olanzapine Approved, Investigational Phase 4,Phase 3 132539-06-1 4585
18
Pramipexole Approved, Investigational Phase 4 104632-26-0 119570 59868
19
Ropinirole Approved, Investigational Phase 4 91374-21-9, 91374-20-8 5095 497540
20
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
21
Naratriptan Approved, Investigational Phase 4 121679-13-8, 143388-64-1 4440
22 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
24 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
25 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
29 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
30 Dopamine Uptake Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
33 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
34 GABA Agents Phase 4
35 Anticonvulsants Phase 4,Phase 2
36 Antimanic Agents Phase 4,Phase 3
37 Hypoglycemic Agents Phase 4,Phase 2
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Narcotics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Narcotic Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Sodium Channel Blockers Phase 4
42 Diuretics, Potassium Sparing Phase 4
43 Cytochrome P-450 CYP3A Inducers Phase 4
44 Serotonin 5-HT2 Receptor Antagonists Phase 4,Not Applicable
45 Dopamine agonists Phase 4,Phase 3,Phase 1,Not Applicable
46 Dopamine D2 Receptor Antagonists Phase 4,Not Applicable
47 Antidepressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
48 Serotonin 5-HT1 Receptor Agonists Phase 4,Not Applicable
49 Serotonin Receptor Agonists Phase 4,Not Applicable
50 Sympathomimetics Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 259)
# Name Status NCT ID Phase Drugs
1 Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Unknown status NCT02063945 Phase 4 Methylphenidate;Risperidone
2 Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Unknown status NCT00794625 Phase 4 Valproate;Risperidone;Placebo;Stimulant medication
3 Methylphenidate in ADHD With Trichotillomania Unknown status NCT00552266 Phase 4 Methylphenidate
4 Topiramate in the Treatment of Pathological Gambling Unknown status NCT00245583 Phase 4 topiramate (Topomax)
5 The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States. Completed NCT00154362 Phase 4 Oxcarbazepine
6 Trial of Aripiprazole in the Treatment of CD in Adolescents Completed NCT00250705 Phase 4 Aripiprazole
7 Early Prevention of Conduct Problems Completed NCT00051714 Phase 4
8 Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Completed NCT00228046 Phase 4 Divalproex Sodium;Methylphenidate;Dextroamphetamine;Mixed Amphetamine Salts
9 Treatment of Severe Childhood Aggression (The TOSCA Study) Completed NCT00796302 Phase 4 Methylphenidate HCl;Risperidone;Placebo
10 Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings Completed NCT02078596 Phase 4 Divalproex
11 Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa Completed NCT01683253 Phase 4 Levodopa/Carbidopa(200mg/50mg);Dopaminergic Agonists
12 Escitalopram for the Treatment of Self-Injurious Skin Picking Completed NCT00115011 Phase 4 Escitalopram
13 Sertraline and Habit Reversal in the Treatment of Patients With Trichotillomania Completed NCT00118014 Phase 4 Sertraline
14 Treatment of Pathological Gambling With Naltrexone Pharmacotherapy and Brief Intervention Completed NCT01528007 Phase 4 Naltrexone pharmacotherapy;Placebo
15 Acamprosate in the Treatment of Pathological Gambling Completed NCT00571103 Phase 4 acamprosate
16 Olanzapine in the Treatment of Hair Pulling (Trichotillomania) Completed NCT00182507 Phase 4 Olanzapine
17 Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany Completed NCT00406354 Phase 4 Atomoxetine;Placebo
18 A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Completed NCT00190775 Phase 4 Atomoxetine Hydrochloride;Placebo
19 Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
20 Does Pharmacological Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults Enhance Parenting Performance? Completed NCT01127607 Phase 4 lisdexamfetamine
21 Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Completed NCT02048241 Phase 4 Intuniv
22 Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder Recruiting NCT02566824 Phase 4 Methylphenidate or amphetamine product
23 Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk Not yet recruiting NCT03781765 Phase 4 Methylphenidate;Atomoxetine
24 Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order Terminated NCT00282165 Phase 4 naratriptan;placebo
25 Multidimensional Treatment Foster Care for Adolescents Withdrawn NCT01726361 Phase 4
26 Long-Term Lithium Treatment for Aggressive Conduct Disorder Completed NCT00000385 Phase 3 Lithium;Placebo
27 A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation Completed NCT00266552 Phase 3 risperidone
28 A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation Completed NCT00250354 Phase 3 Risperidone oral solution
29 Randomized Control Trial of an Animal-Assisted Intervention With Adjudicated Youth Completed NCT01594606 Phase 3
30 Treating Tobacco Dependence in Adolescents With Co-occurring Psychiatric Disorders Completed NCT00618943 Phase 3
31 Adventure: Teacher Delivered Personality-targeted Interventions for Substance Misuse Completed NCT00776685 Phase 2, Phase 3
32 Personality-targeted Interventions for Adolescent Alcohol Misuse Completed NCT00344474 Phase 2, Phase 3
33 Omega-3 Supplements to Reduce Antisocial Behaviour in Young Offenders Completed NCT03627312 Phase 2, Phase 3
34 Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Completed NCT01416805 Phase 3
35 Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone. Completed NCT00399698 Phase 3 Risperdal
36 A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder Completed NCT00922636 Phase 2, Phase 3 LY2216684;Methylphenidate;Placebo (tablet);Placebo (capsule)
37 Safety and Efficacy Trial of Olanzapine in Outpatients With Pathological Gambling Completed NCT00438776 Phase 3 olanzapine;sugar pill
38 Minimal and Brief Treatments for Pathological Gamblers Completed NCT00203645 Phase 3
39 Nalmefene Gambling Study: Study of Nalmefene HCl in the Treatment of Pathological Gambling Completed NCT00132119 Phase 2, Phase 3 nalmefene HCl
40 Drug Treatment for Pathologic Gambling Disorder Completed NCT00053677 Phase 3 Naltrexone;Placebo
41 Treatment of Children With Peer Related Aggressive Behavior Completed NCT01406067 Phase 3
42 The Effect of Transcranial Direct Current Stimulation on Decision Making and Cognitive Flexibility in Gambling Disorder Completed NCT03477799 Phase 3
43 Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors Recruiting NCT03530800 Phase 2, Phase 3 Dronabinol;Placebo
44 Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders Recruiting NCT03146130 Phase 3
45 Modulating Inhibitory Control Networks in Gambling Disorder With Theta Burst Stimulation Recruiting NCT03669315 Phase 3
46 How the Adolescent Inpatients Are Rehabilitated After Discharge Terminated NCT01709526 Phase 2, Phase 3
47 A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder Terminated NCT00965419 Phase 2, Phase 3 Edivoxetine
48 Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling Unknown status NCT01340274 Phase 2
49 Testing a New Therapy for Trichotillomania Unknown status NCT00872742 Phase 2
50 Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study Unknown status NCT02934919 Phase 2 Nalmefene

Search NIH Clinical Center for Conduct Disorder

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: conduct disorder

Genetic Tests for Conduct Disorder

Anatomical Context for Conduct Disorder

MalaCards organs/tissues related to Conduct Disorder:

42
Brain, Testes, Skin, Amygdala, Cortex, Eye, Heart

Publications for Conduct Disorder

Articles related to Conduct Disorder:

(show top 50) (show all 912)
# Title Authors Year
1
Should childhood conduct disorder be necessary to diagnose antisocial personality disorder in adults? ( 30699216 )
2019
2
Emotional valence detection in adolescents with oppositional defiant disorder/conduct disorder or autism spectrum disorder. ( 30680520 )
2019
3
Comorbidity of Bipolar-I Disorder and Conduct Disorder: A Familial Risk Analysis. ( 30758064 )
2019
4
Clozapine in the Treatment of Aggression in Conduct Disorder in Children and Adolescents: A Randomized, Double-blind, Controlled Trial. ( 30690939 )
2019
5
White matter microstructure of the extended limbic system in male and female youth with conduct disorder. ( 30696514 )
2019
6
Clinical Practice Guidelines for the management of conduct disorder. ( 30745702 )
2019
7
Risky business! Behavioral bias and motivational salience of rule-violations in children with conduct disorder. ( 30791350 )
2019
8
Regional Homogeneity Abnormalities in Early-Onset and Adolescent-Onset Conduct Disorder in Boys: A Resting-State fMRI Study. ( 30792633 )
2019
9
The Risk of Making False Confessions: The Role of Developmental Disorders, Conduct Disorder, Psychiatric Symptoms, and Compliance. ( 30895906 )
2019
10
Assessment of the frequency criterion for the diagnosis of non-suicidal self-injury disorder in female adolescents with conduct disorder. ( 29957550 )
2018
11
Episodic memory and consciousness in antisocial personality disorder and conduct disorder. ( 29353574 )
2018
12
Conduct disorder in adolescent females: current state of research and study design of the FemNAT-CD consortium. ( 29948230 )
2018
13
Conduct Disorder and Neighborhood Effects. ( 29350996 )
2018
14
Executive Attention and Empathy-Related Responses in Boys with Oppositional Defiant Disorder or Conduct Disorder, With and Without Comorbid Anxiety Disorder. ( 29752662 )
2018
15
MAOA genotype influences neural response during an inhibitory task in adolescents with conduct disorder. ( 29855796 )
2018
16
Does the course of manic symptoms in pediatric bipolar disorder impact the course of conduct disorder? Findings from four prospective datasets. ( 29890451 )
2018
17
A longitudinal analysis of shooter games and their relationship with conduct disorder and cself-reported delinquency. ( 29853012 )
2018
18
Social skills training and play group intervention for children with oppositional-defiant disorders/conduct disorder: Mediating mechanisms in a head-to-head comparison. ( 29347904 )
2018
19
Distinguishing Adolescents With Conduct Disorder From Typically Developing Youngsters Based on Pattern Classification of Brain Structural MRI. ( 29740296 )
2018
20
Sex Differences in the Genetic and Environmental Influences on Self-Reported Non-aggressive and Aggressive Conduct Disorder Symptoms in Early and Middle Adolescence. ( 29948512 )
2018
21
Pregnancy risk factors in relation to oppositional-defiant and conduct disorder symptoms in the Avon Longitudinal Study of Parents and Children. ( 29550610 )
2018
22
Do Callous-Unemotional Traits and Conduct Disorder Symptoms Predict the Onset and Development of Adolescent Substance Use? ( 29455341 )
2018
23
Oppositional defiant disorder/conduct disorder co-occurrence increases the risk of Internet addiction in adolescents with attention-deficit hyperactivity disorder. ( 29865863 )
2018
24
Anatomy of the dorsal default-mode network in conduct disorder: Association with callous-unemotional traits. ( 29413533 )
2018
25
Amygdala-orbitofrontal structural and functional connectivity in females with anxiety disorders, with and without a history of conduct disorder. ( 29348532 )
2018
26
Reciprocal Relations Between Parenting Behaviors and Conduct Disorder Symptoms in Preschool Children. ( 29468356 )
2018
27
Serum levels of cortisol, dehydroepiandrosterone, and oxytocin in children with attention-deficit/hyperactivity disorder combined presentation with and without comorbid conduct disorder. ( 29324397 )
2018
28
Impact of Drug Adherence on Oppositional Defiant Disorder and Conduct Disorder Among Patients With Attention-Deficit/Hyperactivity Disorder. ( 30192445 )
2018
29
Facial Emotion Recognition and Eye Gaze in Attention-Deficit/Hyperactivity Disorder With and Without Comorbid Conduct Disorder. ( 30071977 )
2018
30
Saliva oxytocin, cortisol, and testosterone levels in adolescent boys with autism spectrum disorder, oppositional defiant disorder/conduct disorder and typically developing individuals. ( 30201120 )
2018
31
Preclinical models of conduct disorder - principles and pharmacologic perspectives. ( 27238913 )
2018
32
The pharmacological treatment of aggression in children and adolescents with conduct disorder. Do callous-unemotional traits modulate the efficacy of medication? ( 28137460 )
2018
33
Preventing Conduct Disorder and Callous Unemotional Traits: Preliminary Results of a School Based Pilot Training Program. ( 28144810 )
2018
34
Can laboratory animals violate behavioural norms? Towards a preclinical model of conduct disorder. ( 28167096 )
2018
35
An update on the global prevalence of conduct disorder (2011-2017): Study protocol for a systematic review and meta-analysis. ( 30031216 )
2018
36
Independent predictors of mortality in adolescents ascertained for conduct disorder and substance use problems, their siblings and community controls. ( 30091161 )
2018
37
Distinct brain structure and behavior related to ADHD and conduct disorder traits. ( 30108313 )
2018
38
Focused issue on conduct disorder and aggressive behaviour. ( 30143888 )
2018
39
Multivoxel pattern analysis of structural MRI in children and adolescents with conduct disorder. ( 30145719 )
2018
40
Nosology and subtypes of conduct disorder. ( 30166685 )
2018
41
Understanding the Demographic Predictors and Associated Comorbidities in Children Hospitalized with Conduct Disorder. ( 30181470 )
2018
42
Sex Differences in Spontaneous Brain Activity in Adolescents With Conduct Disorder. ( 30214422 )
2018
43
Commentary on Border et al. (2018): The public health burden of conduct disorder, early mortality and criminal justice involvement. ( 30215875 )
2018
44
Conduct Disorder: Recognition and Management. ( 30365289 )
2018
45
Altered Neuronal Responses During an Affective Stroop Task in Adolescents With Conduct Disorder. ( 30405475 )
2018
46
Associations Between Conduct Disorder, Neurodevelopmental Problems and Psychopathic Personality Traits in a Swedish Twin Youth Population. ( 30459483 )
2018
47
Valence, arousal or both? Shared emotional deficits associated with Attention Deficit and Hyperactivity Disorder and Oppositional/Defiant-Conduct Disorder symptoms in school-aged youth. ( 30529288 )
2018
48
Atypical Frontotemporal Connectivity of Cognitive Empathy in Male Adolescents With Conduct Disorder. ( 30687205 )
2018
49
A Retrospective Study of Long Acting Risperidone Use to Support Treatment Adherence in Youth with Conduct Disorder. ( 29073744 )
2017
50
Conduct Disorder ( 29261891 )
2017

Variations for Conduct Disorder

Expression for Conduct Disorder

Search GEO for disease gene expression data for Conduct Disorder.

Pathways for Conduct Disorder

Pathways related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 ALDH2 CAMK2A COMT GRIN1 MAOA SLC6A3
2
Show member pathways
12.63 CAMK2A COMT DRD2 DRD4 DRD5 GRIN1
3 12.38 CAMK2A COMT DBH GRIN1 POMC TPH1
4 12.21 DRD2 DRD4 DRD5 GRIN1
5 12.18 CAMK2A DRD2 DRD5 GRIN1 OXTR
7 12.1 CAMK2A DRD5 GRIN1 OXTR
8 12.02 GRIN1 MAOA SLC6A4 TPH1
9
Show member pathways
12.02 CAMK2A DRD2 DRD4 DRD5 GRIN1
10 11.84 MAOA SLC6A4 TPH1
11
Show member pathways
11.82 DRD2 DRD4 DRD5
12
Show member pathways
11.72 ALDH2 MAOA TPH1
13
Show member pathways
11.72 CAMK2A DRD2 GRIN1 MAOA SLC6A3
14 11.71 DBH MAOA TPH1
15
Show member pathways
11.62 COMT DBH MAOA
16 11.52 CAMK2A GRIN1 RBFOX1
17
Show member pathways
11.26 DBH MAOA SLC6A3 SLC6A4
18 11.12 MAOA SLC6A4 TPH1
19 10.95 DRD2 DRD5
20
Show member pathways
10.83 ALDH2 COMT MAOA
21 10.74 COMT MAOA
22
Show member pathways
10.7 ALDH2 MAOA
23
Show member pathways
10.6 COMT DBH MAOA TPH1
24
Show member pathways
10.44 ALDH2 COMT MAOA SLC6A3 SLC6A4

GO Terms for Conduct Disorder

Cellular components related to Conduct Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.87 DRD2 DRD4 DRD5 GRIN1 OXTR SLC6A3
2 dendrite GO:0030425 9.65 CAMK2A COMT DRD2 DRD4 GRIN1
3 integral component of presynaptic membrane GO:0099056 9.54 DRD2 SLC6A3 SLC6A4
4 dopaminergic synapse GO:0098691 9.4 DRD2 SLC6A3
5 neuron projection GO:0043005 9.35 CAMK2A GRIN1 SLC6A3 SLC6A4 TPH1
6 integral component of postsynaptic membrane GO:0099055 9.33 DRD2 SLC6A3 SLC6A4
7 dendritic spine GO:0043197 8.92 CAMK2A COMT DRD2 GRIN1

Biological processes related to Conduct Disorder according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.88 COMT DRD2 OXTR SLC6A3 SLC6A4
2 response to organic cyclic compound GO:0014070 9.85 COMT OXTR SLC6A3
3 response to ethanol GO:0045471 9.82 DRD2 GRIN1 SLC6A3
4 cellular calcium ion homeostasis GO:0006874 9.81 DRD4 DRD5 GRIN1
5 locomotory behavior GO:0007626 9.8 DBH DRD2 SLC6A3
6 memory GO:0007613 9.76 DBH GRIN1 OXTR SLC6A4
7 visual learning GO:0008542 9.71 DBH DRD2 GRIN1
8 negative regulation of blood pressure GO:0045776 9.69 DRD2 DRD5
9 arachidonic acid secretion GO:0050482 9.68 DRD2 DRD4
10 regulation of long-term neuronal synaptic plasticity GO:0048169 9.68 DRD2 GRIN1
11 behavioral response to cocaine GO:0048148 9.68 DRD2 DRD4
12 regulation of neuronal synaptic plasticity GO:0048168 9.68 CAMK2A GRIN1
13 response to pain GO:0048265 9.67 COMT DBH
14 dopamine receptor signaling pathway GO:0007212 9.67 DRD2 DRD4
15 social behavior GO:0035176 9.67 DRD4 GRIN1 OXTR SLC6A4
16 negative regulation of protein secretion GO:0050709 9.66 DRD2 DRD4
17 response to iron ion GO:0010039 9.66 DRD2 SLC6A3
18 synaptic transmission, dopaminergic GO:0001963 9.65 DRD2 DRD5
19 startle response GO:0001964 9.65 DRD2 GRIN1
20 neurotransmitter biosynthetic process GO:0042136 9.64 SLC6A3 SLC6A4
21 maternal behavior GO:0042711 9.63 DBH OXTR
22 suckling behavior GO:0001967 9.63 GRIN1 OXTR
23 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.62 DRD2 DRD4
24 catecholamine metabolic process GO:0006584 9.61 COMT MAOA
25 neurotransmitter catabolic process GO:0042135 9.61 COMT MAOA
26 dopamine metabolic process GO:0042417 9.61 COMT DRD2 DRD4
27 regulation of dopamine metabolic process GO:0042053 9.6 DRD4 SLC6A3
28 adenohypophysis development GO:0021984 9.59 DRD2 SLC6A3
29 monoamine transport GO:0015844 9.58 SLC6A3 SLC6A4
30 negative regulation of voltage-gated calcium channel activity GO:1901386 9.58 DRD2 DRD4
31 prepulse inhibition GO:0060134 9.58 DRD2 GRIN1 SLC6A3
32 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.57 DRD2 DRD5
33 regulation of systemic arterial blood pressure by vasopressin GO:0001992 9.56 DRD5 OXTR
34 response to cocaine GO:0042220 9.56 DRD2 DRD5 OXTR SLC6A3
35 sperm ejaculation GO:0042713 9.55 OXTR SLC6A4
36 fear response GO:0042596 9.52 DBH DRD4
37 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.51 DRD2 DRD4
38 behavioral response to ethanol GO:0048149 9.5 DBH DRD2 DRD4
39 response to histamine GO:0034776 9.49 DRD2 DRD4
40 associative learning GO:0008306 9.46 DBH DRD2 DRD5 GRIN1
41 dopamine catabolic process GO:0042420 9.26 COMT DBH MAOA SLC6A3
42 response to amphetamine GO:0001975 9.1 DBH DRD2 DRD4 DRD5 GRIN1 OXTR

Molecular functions related to Conduct Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.71 DRD2 GRIN1 POMC SLC6A3
2 drug binding GO:0008144 9.43 DRD2 DRD4 SLC6A3
3 neurotransmitter:sodium symporter activity GO:0005328 9.37 SLC6A3 SLC6A4
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.32 DRD2 DRD4
5 monoamine transmembrane transporter activity GO:0008504 9.16 SLC6A3 SLC6A4
6 dopamine neurotransmitter receptor activity GO:0004952 9.13 DRD2 DRD4 DRD5
7 dopamine binding GO:0035240 8.92 DRD2 DRD4 DRD5 SLC6A3

Sources for Conduct Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....